LAG3 and melanoma: Despite these clinical successes, 40–60% of melanoma patients treated with different ICB strategies inhibiting, not only PD-1/PD-L1, but also Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) or Lymphocyte Activation Gene 3 (LAG-3), even in combination, do not achieve a complete therapeutic response, and several responders undergo relapse (Kalaora et al, 2022).